Multiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia A
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Adeno-associated virus (AAV)-mediated gene therapy is under investigation as a therapeutic option for persons with hemophilia A. Efficacy and safety data include 3 years of follow-up after a single administration of AAV5-hFVIII-SQ. METHODS: We report durable efficacy, long-term safety, and clinical and biologic results in 15 adults with severe hemophilia A (factor VIII level, ≤1 IU per deciliter) who had received a single infusion of AAV5-hFVIII-SQ at various dose levels. We evaluated the factor VIII level, annualized rate of bleeding events, use of factor VIII, safety, expression kinetics, and biologic markers of AAV transduction for up to 3 years. RESULTS: vg per kilogram) had a median factor VIII expression of 13 IU per deciliter; the median annualized rate of bleeding events was 0, and the median use of factor VIII was reduced from 155.5 infusions to 0.5 infusions per year. Bleeding in target joints resolved in five of six participants. The factor VIII pharmacodynamic profiles reflected cellular turnover in the blood and molecular events leading to episomal DNA stabilization for persistent expression, findings that are consistent with previous observations in two model systems. Transgene-derived human factor VIII (hFVIII) protein activity mirrored native hFVIII in hemostatic ability. No inhibitor development, thromboses, deaths, or persistent changes in liver-function tests were observed. CONCLUSIONS: vg per kilogram of the gene therapy. (Funded by BioMarin Pharmaceutical; ClinicalTrials.gov number, NCT02576795; EudraCT number, 2014-003880-38.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Approximately 5 subjects across 3 trials experienced self-limited, vector-infusion reactions at doses of 2 × 1012−6 × 1013 vg/kg, characterized by fever, myalgias, and/or hypotension, which appear consistent with an innate immune response.141,150,152”
From Current clinical applications of in vivo gene therapy with AAVs (2021) · cites this paper as [150]
In the citing paper
“multiple HA and HB trials have demonstrated ≥10-fold variability in FVIII:C/FIX:C with the same vector and dose (Harrington et al., 2020, WFH Virtual Summit, conference).145,149,150,153”
From Current clinical applications of in vivo gene therapy with AAVs (2021) · cites this paper as [150]
In the citing paper
“Corticosteroids are the most commonly used agents to resolve transaminitis, however, its relationship with resolution by corticosteroids and T-cell response are not always clear as observed in a hemophilia A trial (28, 105).”
From Immunomodulation in Administration of RAAV: Preclinical and Clinical Adjuvant Pharmacotherapies (2021) · cites this paper as [105]
Citations
Cites
Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy
Mendell, J. R., Al-Zaidy, S., Shell, R., Arnold, W. D., Rodino-Klapac, L. R., Prior, T. W., Lowes, L., Alfano, L., Berry, K., Church, K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706198 · Cited by 2,381
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Self-citationAnalysis of AAV Serotypes 1–9 Mediated Gene Expression and Tropism in Mice After Systemic Injection
Zincarelli, C., Soltys, S., Rengo, G., & Rabinowitz, J. E. (2008) · Molecular Therapy · doi:10.1038/mt.2008.76 · Cited by 1,490
Long-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B
Nathwani, A. C., Reiss, U. M., Tuddenham, E. G. D., Rosales, C., Chowdary, P., McIntosh, J., Della Peruta, M., Lheriteau, E., Patel, N., Raj, D., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407309 · Cited by 1,273
Self-citationEffect of genome size on AAV vector packaging
Wu, Z., Yang, H., & Colosi, P. (2010) · Molecular Therapy · doi:10.1038/mt.2009.255 · Cited by 1,029
Definitions in hemophilia: communication from the SSC of the ISTH
Blanchette, V. S., Key, N. S., Ljung, L. R., Manco‐Johnson, M. J., van den Berg, H. M., & Srivastava, A. (2014) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12672 · Cited by 761
Nucleotide sequence and organization of the adeno-associated virus 2 genome
Srivastava, A., Lusby, E. W., & Berns, K. I. (1983) · Journal of Virology · doi:10.1128/jvi.45.2.555-564.1983 · Cited by 721
AAV5–Factor VIII Gene Transfer in Severe Hemophilia A
Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G. F., Wong, W. Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708483 · Cited by 694
Self-citationAntioxidants reduce endoplasmic reticulum stress and improve protein secretion
Malhotra, J. D., Miao, H., Zhang, K., Wolfson, A., Pennathur, S., Pipe, S. W., & Kaufman, R. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809677105 · Cited by 673
Nakai, H., Yant, S. R., Storm, T. A., Fuess, S., Meuse, L., & Kay, M. A. (2001) · Journal of Virology · doi:10.1128/jvi.75.15.6969-6976.2001 · Cited by 478
Research works printed but not linked: 2
- Torres R, Patton K, Holcomb J, Zoog S, Russell C, Vettermann C. Characterization of AAV5-FVIII-SQ vector DNA in human blood by real-time and Droplet Digital PCR. Mol Ther 2019;27(4):Suppl 1:436-436.
- Fong S, Handyside B, Sihn C-R, et al. The potential for induction of ER stress response by an AAV5-based construct of B-domain deleted FVIII is dependent on the strength of the hepatic specific promoter. Mol Ther 2018;26(5):Suppl 1:375-376.
Cited by
Items 201–300 of 453
Practical aspects of inner ear gene delivery for research and clinical applications
Lee, S., Dondzillo, A., Gubbels, S. P., & Raphael, Y. (2020) · Hearing Research · doi:10.1016/j.heares.2020.107934 · Cited by 17
McNulty, M. J., Silberstein, D. Z., Kuhn, B. T., Padgett, H. S., Nandi, S., McDonald, K. A., & Cross, C. E. (2020) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2020.11.030 · Cited by 17
From Transcriptomics to Treatment in Inherited Optic Neuropathies
Gilhooley, M. J., Owen, N., Moosajee, M., & Yu‐Wai‐Man, P. (2021) · Genes · doi:10.3390/genes12020147 · Cited by 18
Spadarella, G., Minno, A. D., Brunetti‐Pierri, N., Mahlangu, J. N., & Minno, G. D. (2020) · Blood Reviews · doi:10.1016/j.blre.2020.100737 · Cited by 19
Liver-directed gene-based therapies for inborn errors of metabolism
Piccolo, P., Rossi, A., & Brunetti‐Pierri, N. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1817375 · Cited by 16
Modern Strategies of Drug Therapy: Multi-Target Drug Delivery, Bioimaging, Diagnostics
Fedorova, O. V., Ovchinnikova, I. G., Rusinov, G. L., Avdeeva, V. V., Zhdanov, А. P., Zhizhin, K. Y., Kuznetsov, N. T., Zakharova, L. Y., Kuznetsova, D. A., Razuvayeva, Y. S., et al. (2025) · Russian Journal of General Chemistry · doi:10.1134/s1070363225606726 · Cited by 18
Fakhiri, J., Landegger, L. D., & Grimm, D. (2020) · Hearing Research · doi:10.1016/j.heares.2020.108092 · Cited by 15
Zou, P. (2022) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.2c00555 · Cited by 15
Dougherty, J. A., & Dougherty, K. M. (2023) · Annals of Pharmacotherapy · doi:10.1177/10600280231202247 · Cited by 19
Mura, V. L., Cardinale, V., CRISTOFARO, R. D., Santis, A. D., Minno, G. D., Fabris, L., Marra, F., Morisco, F., Peyvandi, F., Pompili, M., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024013750 · Cited by 16
Gene therapy in hemophilia: the dawn of a new era
Gualtierotti, R., Giachi, A., Bitto, N., Mura, V. L., & Peyvandi, F. (2024) · Research and Practice in Thrombosis and Haemostasis · doi:10.1016/j.rpth.2024.102640 · Cited by 15
Transduction of modified factor VIII gene improves lentiviral gene therapy efficacy for hemophilia A
Gong, J., Chung, T., Zheng, J., Zheng, H., & Chang, L. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.101397 · Cited by 15
Liu, S., Razon, L., Ritchie, O., Sihn, C., Handyside, B., Berguig, G. Y., Woloszynek, J. R., Zhang, L., Batty, P. A., Lillicrap, D., et al. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.05.008 · Cited by 17
Shifting Paradigms and Arising Concerns in Severe Hemophilia A Treatment
Chandran, R., Tohit, E. R. M., Stanslas, J., Salim, N., Mahmood, T. M. T., & Rajagopal, M. S. (2024) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0043-1778103 · Cited by 14
Haemophilia, the journey in search of a cure. 1960–2020
Nathwani, A. C., & Tuddenham, E. G. D. (2020) · British Journal of Haematology · doi:10.1111/bjh.17155 · Cited by 15
Clinical perspective: Advancing hemophilia treatment through gene therapy approaches
Thornburg, C. D., PIPE, S. W., Cantore, A., Unzu, C., Jones, M., & Miesbach, W. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.04.023 · Cited by 13
Kistner, A., Chichester, J. A., Wang, L., Calcedo, R., Greig, J. A., Cardwell, L. N., Wright, M. C., Couthouis, J., Sethi, S., McIntosh, B. E., et al. (2023) · Gene Therapy · doi:10.1038/s41434-023-00423-z · Cited by 13
Engineered serum markers for non-invasive monitoring of gene expression in the brain
Lee, S., Nouraein, S., Kwon, J. J., Huang, Z., Wojick, J. A., Xia, B., Corder, G. F., & Szablowski, J. O. (2024) · Nature Biotechnology · doi:10.1038/s41587-023-02087-x · Cited by 13
El‐Maarri, O., Jamil, M. A., & Oldenburg, J. (2020) · Hämostaseologie · doi:10.1055/a-1282-2286 · Cited by 13
Qiu, L., Xie, M., Zhou, M., Liu, X., Hu, Z., & Wu, L. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.630353 · Cited by 13
In vivo Gene Therapy to the Liver and Nervous System: Promises and Challenges
Cantore, A., Fraldi, A., Meneghini, V., & Gritti, A. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2021.774618 · Cited by 17
Gene therapy – are we ready now?
Kaczmarek, R. (2022) · Haemophilia · doi:10.1111/hae.14530 · Cited by 15
Emerging therapeutic potential of adeno-associated virus-mediated gene therapy in liver fibrosis
Bu, F., Jia, P., Zhu, Y. Y., Yang, Y., Meng, H., Bi, Y., Huang, C., & Li, J. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.06.009 · Cited by 14
Long-term prophylaxis: what are our options and how to define success?
Manco‐Johnson, M. J., & Warren, B. B. (2022) · Hematology · doi:10.1182/hematology.2022000397 · Cited by 14
Valoctocogene roxaparvovec gene transfer in participants with HIV
Ragni, M. V., Majerus, E. M., Fong, S., Yates, B., Scheeler, S., Razon, L., Yu, H. J., Reddy, D. B., & Robinson, T. M. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022008948 · Cited by 13
Hu, Z., Wu, Y. C., Xiao, R., Zhao, J., Chen, Y., Wu, L., Zhou, M., & Liang, D. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1115831 · Cited by 16
Oral Treatment of Obesity by GLP-1 and Its Analogs
Holler, N., Ruseska, I., Schachner-Nedherer, A.-L., Zimmer, A., & Petschacher, C. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17121596 · Cited by 13
Platelet-targeted gene therapy induces immune tolerance in hemophilia and beyond
Kumar, S., Schroeder, J. A., & Shi, Q. (2023) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2023.07.025 · Cited by 13
Han, Z., Yi, X., Li, J., Liao, D., Gao, G., & Ai, J. (2024) · Human Gene Therapy · doi:10.1089/hum.2023.208 · Cited by 12
Gene Therapy in Hemophilia A: Achievements, Challenges, and Perspectives
Bala, N. S., & Thornburg, C. D. (2024) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0044-1785483 · Cited by 14
Konkle, B. A., Peyvandi, F., Foster, G. R., Hermans, C. R. J. R., Mura, V. L., Leavitt, A. D., Lillicrap, D., Mahlangu, J. N., Ozelo, M. C., Pipe, S. W., et al. (2025) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2025.02.042 · Cited by 15
Wu, F., He, W., Xiao, Y., Wu, Q., Zhang, Q., Zhang, T., Xu, L., & Pang, X. (2025) · Advanced Science · doi:10.1002/advs.202408397 · Cited by 17
Escape or Fight: Inhibitors in Hemophilia A
Merlin, S., & Follenzi, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00476 · Cited by 14
Redefining prophylaxis in the modern era
Mahlangu, J. N., Blanchette, V. S., & Klamroth, R. (2020) · Haemophilia · doi:10.1111/hae.14035 · Cited by 12
Gene therapy for neuromuscular disorders: prospects and ethics
Ryan, M. M. (2021) · Archives of Disease in Childhood · doi:10.1136/archdischild-2020-320908 · Cited by 15
Development of an Adeno-Associated Virus-Vectored SARS-CoV-2 Vaccine and Its Immunogenicity in Mice
Qin, X., Li, S., Li, X., Pei, D., Liu, Y., Ding, Y., Liu, L., Bi, H., Shi, X., Guo, Y., et al. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.802147 · Cited by 12
Liver gene therapy with intein‐mediated F8 trans‐splicing corrects mouse haemophilia A
Esposito, F., Lyubenova, H., Tornabene, P., Auricchio, S., Iuliano, A., Nusco, E., Merlin, S., Olgasi, C., Manni, G., Gargaro, M., et al. (2022) · EMBO Molecular Medicine · doi:10.15252/emmm.202115199 · Cited by 13
Expectation and loss when gene therapy for haemophilia is not an option: An exigency sub‐study
Fletcher, S. J., Jenner, K., Holland, M., & Khair, K. (2023) · Haemophilia · doi:10.1111/hae.14774 · Cited by 12
Chatterjee, S., Bhattacharya, M., Lee, S., & Chakraborty, C. (2023) · Current Research in Biotechnology · doi:10.1016/j.crbiot.2023.100150 · Cited by 15
The Evolution of Gene Therapy in the Treatment of Metabolic Liver Diseases
Moscoso, C. G., & Steer, C. J. (2020) · Genes · doi:10.3390/genes11080915 · Cited by 14
Agboola, F. O., Rind, D. M., Walton, S. M., Herron-Smith, S., Quach, D., & Pearson, S. D. (2021) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2021.27.5.667 · Cited by 12
Treatment of haemophilia: From replacement to gene therapy
Páramo, J. A. (2021) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2021.04.013 · Cited by 12
Tratamiento moderno de la hemofilia y el desarrollo de terapias innovadoras
Ruiz‐Sàez, A. (2021) · Investigación Clínica · doi:10.22209/ic.v62n1a07 · Cited by 17
Minno, G. D., Miesbach, W., Castaman, G., & Peyvandi, F. (2024) · Haematologica · doi:10.3324/haematol.2023.284622 · Cited by 21
Hepatitis after gene therapy, what are the possible causes?
Maina, A. M., & Foster, G. R. (2024) · Journal of Viral Hepatitis · doi:10.1111/jvh.13919 · Cited by 14
Therapeutic advances in hemophilia: from molecular innovation to patient-centered global care
Dushimova, Z., Pashimov, M., Kaibullayeva, J. A., Danyarova, L., Kultanova, E., Abdilova, G., & Mustapayeva, N. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1618464 · Cited by 15
Role of Essential Metal Ions in AAV Vector-Mediated Transduction
Rambhai, H. K., Ashby, F. J., Qing, K., & Srivastava, A. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.05.019 · Cited by 11
RNAi targeting heparin cofactor II promotes hemostasis in hemophilia A
Lin, W., Zhu, R., Zhang, Z., Lu, X., Wang, H., He, W., Hu, Y., & Tang, L. V. (2021) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2021.03.022 · Cited by 11
Barbon, S., Stocco, E., Rajendran, S., Zardo, L., Macchi, V., Grandi, C., Tagariello, G., Porzionato, A., Radossi, P., De, R., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137282 · Cited by 11
Intraosseous delivery of platelet-targeted factor VIII lentiviral vector in humanized NBSGW mice
Joo, J. H., Wang, X., Singh, S., Chen, C., Li, C., Adair, J. E., Kiem, H., Rawlings, D. J., & Miao, C. H. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022008079 · Cited by 11
Gene therapy in haemophilia: literature review and regional perspectives for Turkey
Kavaklı, K., Antmen, B., Okan, V., Şahin, F., Aytaç, S., Balkan, C., Berber, E., Kaya, Z., Küpesiz, A., & Zülfikar, B. (2022) · Therapeutic Advances in Hematology · doi:10.1177/20406207221104591 · Cited by 12
Minno, G. D., Castaman, G., CRISTOFARO, R. D., Brunetti‐Pierri, N., Pastore, L., Castaldo, G., Trama, U., & Minno, M. N. D. D. (2022) · Blood Reviews · doi:10.1016/j.blre.2022.101011 · Cited by 12
Astermark, J., Buckner, T. W., Frenzel, L., Hatswell, A. J., You, X., Liu, H., Goodman, E., Santos, S., Hawes, C. R., Hinds, D. R., et al. (2023) · Haemophilia · doi:10.1111/hae.14818 · Cited by 11
Advances in Hemophilia A Management
Cho, S., Perry, A. M., Cheng, A. M., Wang, C., & Rico, J. F. (2022) · Advances in Pediatrics · doi:10.1016/j.yapd.2022.03.009 · Cited by 12
Simmons, E. M., Wen, Y., Li, J., Qian, Y., Wong, L. C., Konrad, R. J., & Bivi, N. (2022) · Journal of Immunological Methods · doi:10.1016/j.jim.2022.113397 · Cited by 11
Current and Future Options of Haemophilia A Treatments
Miesbach, W., & Eladly, F. (2021) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1908993 · Cited by 12
Borroni, E., Borsotti, C., Cirsmaru, R. A., Kalandadze, V., Famà, R., Merlin, S., Brown, B. D., & Follenzi, A. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102116 · Cited by 10
Tonetto, E., Cucci, A., Follenzi, A., Bernardi, F., Pinotti, M., & Balestra, D. (2024) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2024.04.020 · Cited by 11
Minno, G. D., Spadarella, G., Maldonato, N. M., Lucia, N. D., Castaman, G., CRISTOFARO, R. D., Santoro, C., Peyvandi, F., Borrelli, A., Lupi, A., et al. (2023) · Blood Reviews · doi:10.1016/j.blre.2023.101118 · Cited by 11
Senthilkumar, M. B., Sarangi, P., Amit, S., Senguttuvan, S., Kumar, N., & Jayandharan, G. R. (2023) · Thrombosis Research · doi:10.1016/j.thromres.2023.09.008 · Cited by 11
Developing AAV-delivered nonsense suppressor tRNAs for neurological disorders
Wang, J., Gao, G., & Wang, D. (2024) · Neurotherapeutics · doi:10.1016/j.neurot.2024.e00391 · Cited by 10
Thornburg, C. D., Adamski, K. N., Cook, K., Vembusubramanian, M., Sendhil, S. R., Hinds, D. R., Chen, E., Sammon, J., Solari, P. G., Garrison, L. P., et al. (2021) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2021.21368 · Cited by 10
Lundgren, T. S., Denning, G., Stowell, S. R., Spencer, H. T., & Doering, C. B. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021006359 · Cited by 13
Advances in gene therapy for hematologic disease and considerations for transfusion medicine
Reddy, O. L., Savani, B. N., Stroncek, D. F., & Panch, S. R. (2020) · Seminars in Hematology · doi:10.1053/j.seminhematol.2020.07.004 · Cited by 16
Pipe, S. W., Kruse‐Jarres, R., Mahlangu, J. N., Pierce, G. F., Peyvandi, F., Kuebler, P., Ford, C. D., Sanabria, F., Ko, R. H., Chang, T. Y., et al. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15186 · Cited by 11
Self-citationFonck, C., Su, C., Arens, J., Koziol, E., Srimani, J. K., Henshaw, J., Tuyl, A. V., Chandra, S. A. M., Vettermann, C., & O’neill, C. A. (2022) · Gene Therapy · doi:10.1038/s41434-022-00318-5 · Cited by 10
Castaman, G., Carulli, C., CRISTOFARO, R. D., Follino, M., Lupi, A., Mancuso, M. E., Mansueto, M. F., Molinari, A. C., Pasquetti, P., Santoro, C., et al. (2022) · Haemophilia · doi:10.1111/hae.14709 · Cited by 9
Gene therapies, uncertainty, and decision-making: thinking about the last mile at the first step
Frederix, G., & ten Ham, R. M. T. (2023) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2023.2245138 · Cited by 9
Lisjak, M., Iaconcig, A., Guarnaccia, C., Vicidomini, A., Moretti, L., Collaud, F., Ronzitti, G., Zentilin, L., & Muro, A. F. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.08.022 · Cited by 10
Ito, K., Tajima, G., Kamisato, C., Tsumura, M., Iwamoto, M., Sekiguchi, Y., Numata, Y., Watanabe, K., Yabe, Y., Kanki, S., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci163464 · Cited by 9
Treatment of Hemophilia — More Amazing Progress
Mannucci, P. M. (2020) · New England Journal of Medicine · doi:10.1056/nejme2024545 · Cited by 10
Eshghi, S., Bakhtiari, M. M., Behfar, M., Izadi, E., Naji, P., Jafari, L., Mohseni, R., Saltanatpour, Z., & Hamidieh, A. A. (2024) · Regenerative Therapy · doi:10.1016/j.reth.2024.12.007 · Cited by 9
Bangolo, A., Amoozgar, B., Zhang, L., Gill, S. K., Milolo, D. L., Kankonde, J. N., Batakamuna, C. M., Tassan, R., Cho, C., Bukasa-Kakamba, J., et al. (2025) · Biomedicines · doi:10.3390/biomedicines13082022 · Cited by 8
Overview of gene therapy for hemophilia: questions and answers to navigate the innovation
Hoffmann, P., Bitto, N., Mura, V. L., & Miesbach, W. (2025) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2025.12.011 · Cited by 12
Franklin, J., Azzouz, M., & Shaw, P. J. (2020) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2020.1835638 · Cited by 9
Ultra-sensitive AAV capsid detection by immunocapture-based qPCR following factor VIII gene transfer
Sandza, K., Clark, A., Koziol, E., Akeefe, H., Yang, F., Holcomb, J., Patton, K., Hammon, K., Mitchell, N., Wong, W. Y., et al. (2021) · Gene Therapy · doi:10.1038/s41434-021-00287-1 · Cited by 9
Self-citationTargeted B-domain deletion restores F8 function in human endothelial cells and mice
Hu, Z., Li, Z., Wu, Y. C., Zhao, J., Wu, L., Zhou, M., & Liang, D. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01016-9 · Cited by 10
Ex vivo factor VIII ‐modified proliferating human hepatocytes therapy for haemophilia A
Zhang, K., Wu, N., Cen, J., Li, J., Wang, Z., Xia, Q., & Hui, L. (2023) · Cell Proliferation · doi:10.1111/cpr.13467 · Cited by 9
Non-viral and viral delivery systems for hemophilia A therapy: recent development and prospects
Zangi, A. R., Amiri, A., Pazooki, P., Soltanmohammadi, F., Hamishehkar, H., & Javadzadeh, Y. (2023) · Annals of Hematology · doi:10.1007/s00277-023-05459-0 · Cited by 8
Use of CD19-targeted immune modulation to eradicate AAV-neutralizing antibodies
Doshi, B. S., Markmann, C., Novak, N. C., Rojas, S. J., Davidson, R. J., Chau, J. Q., Wang, W., Carrig, S., Rus, C. M., Samelson‐Jones, B. J., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.003 · Cited by 9
Gene Therapy for Hemophilia A: Where We Stand
Zhou, M., Hu, Z., Zhang, C., Wu, L., Li, Z., & Liang, D. (2020) · Current Gene Therapy · doi:10.2174/1566523220666200806110849 · Cited by 9
Kao, Y., Chen, Y., Fan, H., Tsai, T., Cheng, S., Lai, P., Chen, J., & Chen, C. (2021) · Biomedicines · doi:10.3390/biomedicines9091116 · Cited by 10
Singh, J., Goodman-Vincent, E., & Santosh, P. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24109023 · Cited by 9
Gene therapy 1·0 in haemophilia: effective and safe, but with many uncertainties
Makris, M. (2020) · The Lancet Haematology · doi:10.1016/s2352-3026(20)30035-1 · Cited by 8
Haemophilia gene therapy: experiences and lessons from treated patients
Hermans, C. R. J. R. (2022) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-022-02313-w · Cited by 8
Recent Advances in Gene Therapy for Hemophilia
Pang, X., Fu, J., Zhou, Z., Tang, N., Lau, C., Wen, Y., Chen, P., Zhao, J., & Xue, H. (2025) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/10760296251378455 · Cited by 11
Leavitt, A. D., Mahlangu, J. N., Raheja, P., Symington, E. M., Quon, D. V. K., Giermasz, A., Kenet, G., Lowe, G., Key, N. S., Millar, C. M., et al. (2026) · Research and Practice in Thrombosis and Haemostasis · doi:10.1016/j.rpth.2026.103416 · Cited by 8
Self-citationImmunogenicity of Therapeutic Biological Modalities - Lessons from Hemophilia A Therapies
Nguyen, N. H., Jarvi, N. L., & Balu‐Iyer, S. V. (2023) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2023.05.014 · Cited by 7
Infrastructural considerations of implementing gene therapy for hemophilia in the Nordic context
Astermark, J., Baghaei, F., Strandberg, K., Toplican, P. G., Birkedal, M. F., Grahn, E. E., Hansson, C., Kampmann, P., Lehtinen, A., Täckström, K., et al. (2023) · Therapeutic Advances in Hematology · doi:10.1177/20406207231202306 · Cited by 7
Jiang, F., Zhang, C., Liu, W., Liu, F., Huang, H., Tan, Y. F., & Qin, B. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1301915 · Cited by 9
Health utilities in adults with hemophilia A: A retrospective cohort study
Hirniak, S., Edginton, A. N., Iorio, A., Alsabbagh, M. W., Hajducek, D. M., & Wong, W. W. L. (2024) · Haemophilia · doi:10.1111/hae.14979 · Cited by 7
Self-citationAgarwal, S., Sandza, K., Obrochta, K. M., Vora, M., Bowen, A., Bunch, B., Holcomb, J., Robinson, T. M., Jayaram, K., Russell, C. B., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024013150 · Cited by 7
Self-citationHeterogeneity in Bleeding Tendency and Arthropathy Development in Individuals with Hemophilia
Rehill, A. M., McCluskey, S., O’Donnell, J. S., Dockal, M., Preston, R. J. S., & on behalf of the iPATH Study Group (2021) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0041-1723769 · Cited by 8
Genome editing in the human liver: Progress and translational considerations
Ginn, S. L., Christina, S., & Alexander, I. E. (2021) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2021.01.030 · Cited by 8
Kruse, R. L., Huang, Y., Shum, T., Bai, L., Ding, H., Wang, Z., Selaru, F. M., & Kumbhari, V. (2021) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2021.06.016 · Cited by 7
Bullinger, M., Latibeaudiere, D., Lewis, H. B., Miesbach, W., Nolte, S., O’Hara, J., O’Mahony, B., Pollard, D., Skinner, M. W., & Quinn, J. (2021) · The Journal of Haemophilia Practice · doi:10.17225/jhp00176 · Cited by 7
Zhang, L., Yates, B., Murphy, R., Liu, S., Xie, L. Y., Handyside, B., Sihn, C., Bouwman, T., Galicia, N., Tan, D., et al. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.08.002 · Cited by 8
Hasyim, A. A., Iyori, M., Mizuno, T., Abe, Y.-I., Yamagoshi, I., Yusuf, Y., Syafira, I., Shahnaij, M., Sakamoto, A., Yamamoto, Y., et al. (2022) · Parasitology International · doi:10.1016/j.parint.2022.102652 · Cited by 7
Rana, J., Marsic, D., Zou, C., Muñoz-Melero, M., Li, X., Kondratov, O., Li, N., de Jong, Y. P., Zolotukhin, S., & Biswas, M. (2023) · Human Gene Therapy · doi:10.1089/hum.2022.176 · Cited by 9
Neto, S., Mendes, J. P., Santos, S. B. D., Solbrand, A., Carrondo, M. J. T., Peixoto, C., & Silva, R. J. S. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1183974 · Cited by 9
Metadata
- Authors
- Pasi, K. J., Rangarajan, S., Mitchell, N., Lester, W., Symington, E., Madan, B., Laffan, M., Russell, C. B., Li, M., Pierce, G. F., & Wong, W. Y.
- Affiliations
- From Barts and the London School of Medicine and Dentistry (K.J.P.), Guy’s and St. Thomas’ NHS Foundation Trust (B.M.), and the Centre for Haematology, Imperial College London (M. Laffan), London, University Hospital Southampton, Southampton (S.R.), University Hospitals Birmingham NHS Foundation Trust, Birmingham (W.L.), and Cambridge University Hospitals NHS Foundation Trust, Cambridge (E.S.) — all in the United Kingdom; and BioMarin Pharmaceutical, Novato (N.M., C.B.R., M. Li, W.Y.W.), and private...
- University Hospitals Birmingham NHS Foundation Trust (GB)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-01-02
- Volume
- 382
- Issue
- 1
- Pages
- 29-40
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2998050720
- Cited by
- 448
- References
- 29
- Citations by year
- 2026: 30 · 2025: 52 · 2024: 59 · 2023: 67 · 2022: 96 · 2021: 71 · 2020: 73
- FWCI
- 48.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- Queen Mary Research Online (Queen Mary University of London) (submittedVersion)
- Spiral (Imperial College London) (submittedVersion)
- Funders
- BioMarin Pharmaceutical
- Topics
- Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
- Keywords
- hemophilia A, adeno-associated virus gene therapy, factor VIII, long-term safety, annualized bleeding rate, transgene expression kinetics
- MeSH terms
- Dependovirus, Adult, Coagulants, Factor VIII, Follow-Up Studies, Genetic Vectors, Hemophilia A, Hemorrhage, Humans, Infusions, Intravenous, Male, Middle Aged, Genetic Therapy, Biomarkers, Transgenes, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.